Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 14, 2023 - Issue
Submit an article Journal homepage
324
Views
0
CrossRef citations to date
0
Altmetric
PERSPECTIVES

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Alexandria TM Lee1 Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USAORCID Iconhttps://orcid.org/0000-0002-2618-8131
ORCID Icon &
Saihong Ignatius Ou1 Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1764-4975
ORCID Icon
Pages 71-78 | Received 30 Apr 2023, Accepted 02 Jul 2023, Published online: 07 Jul 2023

References

  • Tan AC, Tan DS. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–625. doi:10.1200/JCO.21.01626
  • Ou SI, Nagasaka M, Brazel D, et al. Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021;14(11):101191. doi:10.1016/j.tranon.2021.101191
  • Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39. doi:10.1016/S0140-6736(17)30565-2
  • Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–1128. doi:10.1016/S1470-2045(14)70362-6
  • Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi:10.1056/NEJMoa1704795
  • Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020;139:195–199. doi:10.1016/j.lungcan.2019.11.025
  • Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. doi:10.1016/j.jtho.2019.03.007
  • Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7(5):437–446. doi:10.1016/S2213-2600(19)30053-0
  • Zhou C, Lu Y, Kim S-W, et al. Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study. Ann Oncol. 2022;33(suppl_9):S1560–S1597. doi:10.1016/annonc/annonc1134
  • Hsu JC, Jaminion F, Guerini E, et al. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. CPT Pharmacomet Syst Pharmacol. 2021;10(11):1357–1370. doi:10.1002/psp4.12702
  • Ahn MJ, Kim HR, Yang JCH, et al. Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic ALK-Inhibitor-naive ALK+ non-small cell lung cancer: final results from the phase III ALTA-1L study. Clin Lung Cancer. 2022;23(8):720–730. doi:10.1016/j.cllc.2022.07.008
  • Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi:10.1056/NEJMoa2027187
  • Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2022;11:S2213–2600(22)00437–4. doi:10.1016/S2213-2600(22)00437-4
  • Zhou Q, Soo RA, Chang G-C, et al. Asian subgroup analysis of the randomized phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced ALK-positive non-small cell lung cancer. JTO Clin Res Rep. 2023;4:100499. doi:10.1016/j.jtocrr.2023.100499
  • Lu S, Zhou Q, Liu X, et al. Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People’s Republic of China. J Thorac Oncol. 2022;17(6):816–826. doi:10.1016/j.jtho.2022.02.014
  • Soo RA, Huat Tan E, Hayashi H, et al. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: subgroup analysis of a global phase 2 trial. Lung Cancer. 2022;169:67–76. doi:10.1016/j.lungcan.2022.05.012
  • Nagasaka M, Ou SI. CROWN 2022 second interim updates: when will be the coronation of lorlatinib? J Thorac Oncol. 2022;2022:1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.